Prevalence of PD-L1 expression is associated with EMAST, density of peritumoral T-cells and recurrence-free survival in operable non-metastatic colorectal cancer
| Autor: | Einar Gudlaugsson, Dordi Lea, Kjetil Søreide, Martin M. Watson, Hanne R. Hagland, Ivar Skaland |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Oncology
Male Cancer Research Survival Colorectal cancer medicine.medical_treatment T-Lymphocytes B7-H1 Antigen Cohort Studies 0302 clinical medicine Recurrence Immunology and Allergy Aged 80 and over biology Middle Aged Prognosis Survival Rate 030220 oncology & carcinogenesis Cohort Original Article Female Microsatellite Instability Colorectal Neoplasms PD-L1 Adult medicine.medical_specialty Immunoscore Immunology EMAST 03 medical and health sciences Median follow-up Internal medicine medicine Biomarkers Tumor Humans Aged business.industry Microsatellite instability Immunotherapy medicine.disease Log-rank test biology.protein Neoplasm Recurrence Local business CD8 030215 immunology Follow-Up Studies |
| Zdroj: | Cancer Immunology, Immunotherapy |
| ISSN: | 1432-0851 0340-7004 |
| Popis: | Introduction Microsatellite instability (MSI) predict response to anti-PD1 immunotherapy in colorectal cancer (CRC). CRCs with MSI have higher infiltration of immune cells related to a better survival. Elevated Microsatellite Alterations at Tetranucleotides (EMAST) is a form of MSI but its association with PD-L1 expression and immune-cell infiltration is not known. Methods A consecutive, observational cohort of patients undergoing surgery for CRC. EMAST and clinicopathological characteristics were investigated against PD-L1, as well as CD3 and CD8 expression in the invasive margin or tumour centre (Immunoscore). Difference in survival between groups was assessed by log rank test. Results A total of 149 stage I–III CRCs patients, with a median follow up of 60.1 months. Patients with PD-L1+ tumours (7%) were older (median 79 vs 71 years, p = 0.045) and had EMAST+ cancers (OR 10.7, 95% CI 2.2–51.4, p = 0.001). Recurrence-free survival was longer in cancers with PD-L1+ immune cells (HR 0.35, 95% CI 0.16–0.76, p = 0.008, independent of EMAST) and high Immunoscore (HR 0.10, 95% CI 0.01–0.72, p = 0.022). Patients expressing PD-L1 in immune cells had longer disease-specific survival (HR 0.28, 95% CI 0.10–0.77, p = 0.014). Conclusions Higher Immunoscore (CD3/CD8 cells) and expression of tumour PD-L1 is found in CRCs with EMAST. Lymphocytic infiltrate and peritumoral PD-L1 expression have prognostic value in CRC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink